



Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA
02210-1862
Tel: 617-341-6100
www.vrtx.com

Notice Regarding Adjustment of 340B Prices for Select Products of Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated “Vertex” has recalculated its 340B ceiling price for the period beginning 2Q 2023 through Q4 2023 for the product listed below due to the recalculation of an estimated provisional 340B ceiling price. Vertex has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Vertex’s recalculation affecting certain 340B Covered Entities for the impacted product(s).

Vertex has determined the credit amount owed to each affected covered entity. Vertex will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Once validated, Apexus will work with the wholesalers to facilitate the processing of credit for the overpayments that the covered entity was charged during the specified periods. If an active wholesaler account cannot be identified, Apexus will work to issue an ACH or check to those entities.

NDC	Product Description
51167-0446-01	TRIKAFTA® (elexacaftor100mg/tezacaftor50mg/ivacaftor75mg; ivacaftor75mg)
51167-0445-01	TRIKAFTA® (elexacaftor80mg/tezacaftor40mg/ivacaftor60mg; ivacaftor59mg)
51167-0770-01	KALYDECO® (ivacaftor, 13.4mg)

If a Covered Entity believes they are due a refund and are not contacted by Apexus by March 31, 2024, you may contact Mary White, Sr Manager - Price Reporting at mary_white@vrtx.com.